非瓣膜性房颤抗凝与经皮冠状动脉介入术后抗栓治疗

Anticoagulant therapy in nonvalvular atrial fibrillation and antithrombotic therapy after percutaneous coronary intervention

房颤和冠心病(CHD)具有许多共同的病理生理机制,且CHD常见的共病之一就是房颤。越来越多房颤患者进行了冠状动脉介入治疗(PCI)后,如何权衡抗凝和抗血小板治疗所带来的缺血与出血的复杂风险,如何选择最佳的治疗方案仍然是临床实践中所遇到的重大难题。本文综述针对近些年来的相关研究,重点讨论了非瓣膜性房颤抗凝与PCI术后抗栓治疗的进展。

Atrial fibrillation(AF) and coronary heart disease(CHD) share many common pathophysiological mechanisms, and one of the most frequent comorbidities of CHD is AF. More and more AF patients receive percutaneous coronary intervention(PCI), how to balance the complicated risks of ischemia and bleeding caused by anticoagulant and antiplatelet therapy, and how to choose the optimal therapeutic program are still the major difficulties encountered in clinical practice. The present article reviews related researches in recent years, and focuses on progress of anticoagulant therapy in nonvalvular atrial fibrillation and antithrombotic therapy after PCI.